Postmenopausal Symptoms Clinical Trial
Official title:
Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients
Verified date | September 2008 |
Source | Upsher-Smith Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to compare the safety and efficacy of USL-221 to placebo for postmenopausal patients.
Status | Completed |
Enrollment | 495 |
Est. completion date | August 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Postmenopausal women - Have moderate to severe hot flashes - Normal Pap Smear Exclusion Criteria: - Abnormal mammogram - Abnormal clinical breast exam - BMI >35 |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Upsher-Smith Laboratories |
Hedrick RE. Low-dose estradiol gel 0.1% for the treatment of vasomotor symptoms associated with menopause. Expert Review of Obstetrics & Gynecology, 3(2): Pages 155-162, Mar 2008.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Daily frequency and severity of moderate to severe vasomotor symptoms | |||
Secondary | vulvar and vaginal atrophy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06369363 -
Estrogen Deficiency on Cardiovascular Risk
|
Early Phase 1 | |
Not yet recruiting |
NCT01170195 -
Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms
|
Phase 1/Phase 2 | |
Completed |
NCT00535288 -
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
|
Phase 3 | |
Recruiting |
NCT06030388 -
Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women
|
N/A | |
Not yet recruiting |
NCT05557799 -
Photobiomodulation in Post Menopause Genitourinary Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT04893226 -
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
|
N/A | |
Completed |
NCT03684096 -
Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes
|
N/A | |
Completed |
NCT01268046 -
Aging and Estrogen on Cortical Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05659693 -
The Effect of Digital Literacy Education Given to Postmenopausal Women on Health Literacy and Quality of Life
|
N/A | |
Completed |
NCT03572153 -
A Mind-Body Intervention for Hot Flash Management
|
N/A | |
Not yet recruiting |
NCT06419972 -
Multimodal Program for Climacteric Women
|
N/A | |
Not yet recruiting |
NCT06197568 -
Open-Label Study of Vaginal AZU-101 in Postmenopausal Women
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03854396 -
Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01361308 -
Efficacy/Safety Study of Brisdelleā¢ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
|
Phase 3 | |
Unknown status |
NCT00905723 -
The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women
|
Phase 3 | |
Recruiting |
NCT05351476 -
Exercise Training and Fat Metabolism in Postmenopausal Women
|
N/A | |
Completed |
NCT06096818 -
Kegel and Abdominal Exercises on Urinary Incontinence Severity, Quality of Life, and Sleep Quality in Menopausal Women
|
N/A | |
Completed |
NCT03150407 -
Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness
|
N/A | |
Recruiting |
NCT06220266 -
Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women
|
Phase 2/Phase 3 | |
Recruiting |
NCT04129060 -
Cholinergic Health After Menopause (CHAMP)
|
Early Phase 1 |